Investigator's Brochure — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Investigator's Brochure — the compiled nonclinical and clinical information given to trial investigators.
Why it exists. Doctors running the trial need a current summary of what is known about the drug's pharmacology, safety, and dosing to treat and consent subjects safely. ICH E6 requires the IB be kept up to date throughout development.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. ICH E6(R3) §7 (Investigator's Brochure)
Investigator's Brochure — GLPI-103
The Investigator's Brochure is the current, one-stop summary of everything known about the drug, given to the physicians at each site so they can dose, monitor, and consent patients safely. It is kept up to date as new data arrive.
| Field | Value |
|---|---|
| Document ID | IB-001 |
| Version | 2.0 (Edition 2) — full |
| Status | Final |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard | ICH E6(R3) §7 (Investigator's Brochure) |
| Confidentiality | Confidential — for investigators / IRB-IEC |
Nonclinical content is
[MOCK — deep-knowledge assumption](see M2.4 / M2.6 / M4). Early clinical content (Phase 1/2) is illustrative[MOCK]; pivotal Phase 3 data are sourced from CSR-301 (outputs/). Parameters cite REF-002.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Clinical / Medical | Initial edition |
| 2.0 | 2026-06-29 | Clinical / Medical | Full edition — expanded properties, nonclinical, human experience, guidance, and reference safety information |
1. Summary
GLPI-103 is a first-in-class synthetic peptide dual agonist of the GLP-1 and apelin (APJ) receptors in development for type 2 diabetes mellitus (T2DM), with lifecycle interest in obesity and heart failure with preserved ejection fraction. Nonclinical studies established robust, dose-dependent glycaemic and body-weight effects exceeding those of a GLP-1 receptor-only comparator, together with favourable cardiometabolic effects and a class-consistent, monitorable safety profile with adequate exposure margins. First-in-human single- and multiple-ascending-dose studies and a Phase 2 dose-finding study confirmed acceptable safety and tolerability, characterized human pharmacokinetics, and demonstrated a clear dose–response. In the pivotal Phase 3 study (GLPI103-301), GLPI-103 (intravenous and oral) was superior to oral semaglutide on HbA1c at Week 52, with substantially greater weight reduction and a manageable, gastrointestinal-predominant safety profile. This brochure provides investigators the information required to conduct studies of GLPI-103 safely and effectively.
2. Introduction
T2DM is a progressive disease in which many patients fail to achieve glycaemic and weight targets and retain substantial cardiometabolic risk. GLP-1 receptor agonists provide glycaemic and weight benefits, but single-mechanism efficacy is limited. GLPI-103 was designed to engage both the GLP-1 receptor (insulinotropic, glucagonostatic, appetite- and gastric-emptying effects) and the APJ receptor (insulin sensitivity, endothelial and myocardial function, anti-inflammatory effects), with the goal of greater metabolic efficacy and cardiometabolic benefit. The development program is summarized in the Clinical Development Plan and Target Product Profile (TPP-001).
3. Physical, Chemical, and Pharmaceutical Properties and Formulation
GLPI-103 is a synthetic peptide dual agonist with a defined primary sequence incorporating fatty-acid acylation (to extend half-life) and non-natural residues (to confer protease resistance). It is supplied as: (a) a sterile aqueous solution for intravenous administration (once weekly), and (b) an immediate-release tablet for oral administration (once daily) formulated with a permeation enhancer to enable peptide absorption. Storage, handling, preparation, and administration are described in the Pharmacy/IMP Manual (TMF-PHARM); quality attributes and stability are summarized in Module 3 (M3 / M3-S / M3-P). [MOCK]
4. Nonclinical Studies
4.1 Nonclinical Pharmacology
In vitro, GLPI-103 is a potent full agonist at both the human GLP-1 receptor (EC₅₀ ≈14 pM) and the human APJ receptor (EC₅₀ ≈48 pM), with no activity at the GIP or glucagon receptors. In vivo, in db/db and diet-induced obese rodent models, GLPI-103 produced dose-dependent reductions in HbA1c and body weight that exceeded those of a GLP-1 receptor-only comparator at matched exposure, with improved insulin sensitivity and favourable cardiometabolic biomarkers (NT-proBNP, hsCRP) consistent with APJ engagement (M4-2.1; M2.6.2). Safety pharmacology (ICH S7A/S7B) demonstrated no central nervous system, respiratory, or QT/hERG liability, with only transient, mechanism-related changes in heart rate.
4.2 Pharmacokinetics and Product Metabolism in Animals
GLPI-103 exhibited approximately dose-proportional exposure in rat and monkey, with a long terminal half-life supporting once-weekly intravenous dosing, adequate oral bioavailability with the permeation enhancer, proteolytic catabolism, negligible cytochrome-P450 involvement (low drug-interaction potential), and low-titre, non-neutralizing anti-drug antibodies (M4-2.2; M2.6.4).
4.3 Toxicology
The toxicology package comprised single- and repeat-dose studies (≤26-week rat and ≤39-week monkey), genotoxicity, carcinogenicity, and reproductive/developmental studies, conducted in compliance with Good Laboratory Practice. Findings were limited to reversible exaggerated-pharmacology effects (reduced food intake and body-weight gain) and injection-site reactions, with no adverse target-organ toxicity at the doses tested; genotoxicity was negative; class-appropriate thyroid C-cell monitoring was incorporated; and reproductive findings were limited to maternal effects. No-observed-adverse-effect levels provided adequate exposure margins to the clinical dose (M4-2.3; M2.4 §4–5).
5. Effects in Humans
5.1 Pharmacokinetics and Metabolism in Humans
Human pharmacokinetics were consistent with the nonclinical profile: a long half-life supporting once-weekly intravenous dosing, oral bioavailability adequate for once-daily dosing with the permeation enhancer, proteolytic catabolism with low drug-interaction potential, and low immunogenicity (M2.7.2). [MOCK]
5.2 Safety and Efficacy in Humans
- Phase 1 (GLPI103-101, SAD, N=40; GLPI103-102, MAD, N=40): acceptable safety and tolerability with no dose-limiting toxicity; dose-dependent pharmacokinetics; pharmacodynamic engagement (HbA1c, body weight, plasma apelin, NT-proBNP, hsCRP) (CSR-101/102).
[MOCK] - Phase 2 (GLPI103-201, N=240, 24 weeks): a clear dose–response for HbA1c reduction with dose-dependent weight loss; gastrointestinal adverse events were the most common and were dose-related; the data supported the Phase 3 doses (CSR-201).
[MOCK] - Phase 3 (GLPI103-301, N=900): GLPI-103 IV and Oral were superior to oral semaglutide on HbA1c change from baseline at Week 52 (IV −0.68%, 95% CI −0.81, −0.55; Oral −0.34%, 95% CI −0.49, −0.23; both p<0.001), with substantially greater weight reduction (−14.5 and −10.3 kg versus −7.6 kg) and higher responder rates. The safety profile was gastrointestinal-predominant; nausea was more frequent with the intravenous formulation (32.3% versus 21.4% for semaglutide; p=0.003), reflecting the expected efficacy–tolerability trade-off managed by titration; hypoglycaemia was infrequent and balanced; and 10 serious adverse events and 2 deaths (none treatment-related) were recorded (CSR-301).
6. Summary of Data and Guidance for the Investigator
The accumulated nonclinical and clinical data indicate that GLPI-103 has a favourable benefit–risk profile in adults with T2DM inadequately controlled on metformin. Investigators should:
- Administer GLPI-103 according to the protocol-defined titration schedule and use dose-modification provisions to manage gastrointestinal tolerability (PROT-301 §6.3; Appendix C).
- Monitor for adverse events of special interest — gastrointestinal events, acute pancreatitis, thyroid C-cell neoplasia (MTC), hypoglycaemia (particularly with concomitant insulin secretagogues), and cardiovascular/heart-rate changes — and follow the AESI and SAE procedures (PROT-301 §10; Appendices B and E).
- Apply the contraindications (personal/family history of MTC or MEN 2; hypersensitivity) and warnings (pancreatitis, gastrointestinal effects, hypoglycaemia) consistently.
- Report serious adverse events to the sponsor within 24 hours per the Safety Management Plan (TMF-SMP).
7. Reference Safety Information (RSI)
The RSI is the official list of expected side effects. It is the yardstick used to decide whether a new adverse event is 'expected' or 'unexpected' — a distinction that changes how fast it must be reported to regulators.
For the assessment of expectedness of serious adverse events, the following adverse reactions are considered expected for GLPI-103:
- Very common / common: nausea, vomiting, diarrhoea, decreased appetite, constipation; injection-site reactions (intravenous formulation); headache; fatigue.
- Common / uncommon: hypoglycaemia (especially in combination with insulin secretagogues). Serious adverse events not listed above are considered unexpected and are subject to expedited reporting (SUSAR) per ICH E2A. Boxed-warning-level risks under class monitoring (thyroid C-cell tumours; pancreatitis) are described in the labeling (USPI/SmPC/KR label). The RSI is reviewed and updated at each IB revision in line with accumulating data and the Risk Management Plan (RMP-EU/US/KR).
Comments (0)
No comments yet. Be the first to say something!